Multicenter, Randomised, Double-Blind Placebo- Controlled Study of Subcutaneous Immunotherapy With Depigmented and Polymerized Allergen Extract of Parietaria Judaica Pollen in Patients With Hypersensitivity to This Pollen.

Trial Profile

Multicenter, Randomised, Double-Blind Placebo- Controlled Study of Subcutaneous Immunotherapy With Depigmented and Polymerized Allergen Extract of Parietaria Judaica Pollen in Patients With Hypersensitivity to This Pollen.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Parietaria pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinitis; Hypersensitivity; Rhinoconjunctivitis
  • Focus Pharmacodynamics
  • Sponsors Laboratorios LETI
  • Most Recent Events

    • 12 Jul 2011 Planned end date changed from 1 Dec 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 23 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top